Cardinal Health, Inc.
At today's price, Cardinal Health, Inc. (CAH) is priced for +5.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Cardinal Health distributes a vast volume of drugs and medical products at a roughly 1% operating margin, a number that looks alarming until you see it is the whole point of the model, not a sign of weakness. • The standout driver is specialty pharmaceuticals, especially oncology and GLP-1 weight-loss drugs, where segment growth above 20% is pulling the entire company higher and offsetting the loss of a major customer contract. • What to watch is whether the medical-products segment turnaround
Is CAH overvalued? See what's priced in →
1,388 institutional managers reported holding CAH in 13F filings for the quarter ended 2026-03-31. Together they hold about 84% of the company; the top 10 hold 43%. 132 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 9.0M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CAH has cut its share count 17.8% over the past five years, spending $5.28B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $2.02 a share annually. Cash returned over the past three years: $1.24B in dividends and $2.28B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CAH over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CAH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-05-06 | -3.7% | -9.2% |
| 2022-08-12 | +10.5% | -1.8% |
| 2022-11-05 | +5.1% | -1.1% |
| 2023-08-16 | -2.8% | +3.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CAH's latest 8-K filings: 2026-04-30 (items 2.02, 7.01, 9.01); 2026-03-23 (items 5.02, 7.01, 9.01); 2026-03-05 (items 5.02); 2026-02-05 (items 2.02, 7.01, 9.01); 2026-01-13 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.